AstraZeneca

From Free net encyclopedia

Template:Infobox Company

AstraZeneca PLCTemplate:Ref (Template:Lse, Template:NYSE), is a large Anglo-Swedish pharmaceutical company formed on 6 April 1999 by the merger of Swedish Astra AB and British Zeneca Group PLC. Zeneca was part of Imperial Chemical Industries prior to a demerger in 1993. AstraZeneca develops, manufactures, and sells pharmaceuticals to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.

Sales in 2004 totalled $21.4 billion, with a profit before tax of $4.8 billion. Total R&D spending was $3.8 billion. The corporate headquarters are in London, UK, the research and development (R&D) headquarters are in Södertälje, Sweden. Major R&D centres are located on three continents in the United States, United Kingdom, Sweden, and India.

The current chief executive of AstraZeneca is David Brennan.Template:Ref He replaced Sir Tom McKillop on the 1st Jan 2006.

Contents

[edit]

Corporate governance

Current members of the board of directors of AstraZeneca are: Peter Bonfield, David Brennan, John Buchanan, Jane Henney, Michele Hooper, Joe Jimenez, Tom McKillop, Håkan Mogren, Erna Möller, Bridget Ogilvie, John Patterson, Louis Schweitzer, Jonathan Symonds, and Marcus Wallenberg.

[edit]

Diversity

AstraZeneca is one of the 100 Best Companies for Working Mothers in 2004 according to Working Mothers magazine.Template:Ref

[edit]

AstraZeneca and Breast Cancer

AstraZeneca is the major sponsor for Breast Cancer Awareness Month which focuses on "early detection and treatment"[1] but does little to address prevention. AstraZeneca is also a leading producer of breast cancer treatment drugs like Tamoxifen and Arimidex

[edit]

Products

AstraZeneca specialises in prescription medicines to fight disease in the several therapeutic areas. Year-on sales information can be found through AstraZeneca annual reports. The following is a list of key products as found on the AstraZeneca website, retrieved 2005-03-27.

This list is incomplete; you can help by expanding it.
[edit]

Controversy over Nexium

Nexium, the successor to Prilosec, has according to some commentators "become a symbol of everything that is wrong with the pharmaceutical industry".Template:Ref

[edit]

Collaborations and alliances

references in this section appear here rather than as endnotes and should be press releases from one or more of the partners; there should be only one entry for each collaboration and only one informational reference in order to maintain a brief yet informative list

[edit]

See also

[edit]

References and notes

  1. Template:Note standard practice is that the name be pronounced as "Astra Zeneca" rather than "Astrazeneca".
  2. Template:Note AstraZeneca PLC (July 28, 2005). The Board of AstraZeneca PLC announces the appointment of David R Brennan as Chief Executive with effect from 1 January 2006 upon the retirement at that time of Sir Tom McKillop. Press release.
  3. Template:Note AstraZeneca Profile. Verified availability February 3, 2006.
  4. Template:Note Gladwell, Malcolm (October 25, 2004). "High Prices: How to think about prescription drugs". The New Yorker. Verified availability August 5, 2005.
[edit]

External links

fr:AstraZeneca sv:AstraZeneca

Retrieved from "http://www.netipedia.com/index.php/AstraZeneca"